Hepcidin—A Potential Novel Biomarker for Iron Status in Chronic Kidney Disease

2009349 citationsJournal Articlegreen Open Access

Authors

Joshua J. Zaritsky · University of California, Los Angeles

Brian Young

He-Jing Wang · University of California, Los Angeles

Mark Westerman · Intrinsic LifeSciences (United States)

Gordana Olbina · Intrinsic LifeSciences (United States)

Elizabeta Nemeth · University of California, Los Angeles

Tomas Ganz · University of California, Los Angeles

Abstract

These findings suggest that increased hepcidin across the spectrum of CKD may contribute to abnormal iron regulation and erythropoiesis and may be a novel biomarker of iron status and erythropoietin resistance.

Topics & Keywords

Iron Metabolism and Disorders Erythropoietin and Anemia Treatment Hemoglobinopathies and Related Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Journal of the American Society of Nephrology

Volume 4, Issue 6, pp. 1051-1056

DOI: 10.2215/cjn.05931108

Field-Weighted Citation Impact: 12.55